{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:45:24Z","timestamp":1792201524727,"version":"4.4.0"},"reference-count":187,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.phrs.2020.105010","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T16:11:40Z","timestamp":1592064700000},"page":"105010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"special_numbering":"C","title":["CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent"],"prefix":"10.1016","volume":"159","author":[{"given":"Jingzhe","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakhos A.","family":"Tannous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Poznansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.phrs.2020.105010_bib0005","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199802123380706","article-title":"Chemokines--chemotactic cytokines that mediate inflammation","volume":"338","author":"Luster","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0010","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1158\/0008-5472.CAN-05-3393","article-title":"Role of the CXCL12\/CXCR4 axis in peritoneal carcinomatosis of gastric cancer","volume":"66","author":"Yasumoto","year":"2006","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.phrs.2020.105010_bib0015","first-page":"3530","article-title":"Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression","volume":"6","author":"Koshiba","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.phrs.2020.105010_bib0020","first-page":"5930","article-title":"Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer","volume":"62","author":"Scotton","year":"2002","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.phrs.2020.105010_bib0025","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1182\/blood-2008-12-196618","article-title":"CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling","volume":"113","author":"Levoye","year":"2009","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0030","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/ni.2812","article-title":"New nomenclature for atypical chemokine receptors","volume":"15","author":"Bachelerie","year":"2014","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.phrs.2020.105010_bib0035","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc1388","article-title":"Cancer and the chemokine network","volume":"4","author":"Balkwill","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0040","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4049\/jimmunol.160.1.180","article-title":"Detection and delineation of CXCR-4 (fusin) as an entry and fusion cofactor for T-tropic [correction of T cell-tropic] HIV-1 by three different monoclonal antibodies","volume":"160","author":"Hori","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2020.105010_bib0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fncel.2014.00065","article-title":"CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems","volume":"8","author":"Guyon","year":"2014","journal-title":"Front. Cell. Neurosci."},{"issue":"12","key":"10.1016\/j.phrs.2020.105010_bib0050","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2165\/11206040-000000000-00000","article-title":"Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma","volume":"71","author":"Keating","year":"2011","journal-title":"Drugs."},{"issue":"19","key":"10.1016\/j.phrs.2020.105010_bib0055","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1158\/1078-0432.CCR-14-0914","article-title":"Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment","volume":"21","author":"Scala","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"5263","key":"10.1016\/j.phrs.2020.105010_bib0060","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1126\/science.272.5263.872","article-title":"HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor","volume":"272","author":"Feng","year":"1996","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.phrs.2020.105010_bib0065","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1084\/jem.186.8.1383","article-title":"Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4","volume":"186","author":"Schols","year":"1997","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0070","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0166-3542(97)00025-9","article-title":"Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin\/CXCR-4","volume":"35","author":"Schols","year":"1997","journal-title":"Antiviral Res."},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0075","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1128\/AAC.38.4.668","article-title":"Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100","volume":"38","author":"De Clercq","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.phrs.2020.105010_bib0080","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd1134","article-title":"The bicyclam AMD3100 story","volume":"2","author":"De Clercq","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"16","key":"10.1016\/j.phrs.2020.105010_bib0085","first-page":"e25","article-title":"Plerixafor for the treatment of WHIM syndrome. Reply","volume":"380","author":"McDermott","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.phrs.2020.105010_bib0090","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1182\/blood.V91.12.4523","article-title":"The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1","volume":"91","author":"M\u00f6hle","year":"1998","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.phrs.2020.105010_bib0095","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/sj.leu.2404684","article-title":"CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment","volume":"21","author":"Juarez","year":"2007","journal-title":"Leukemia."},{"issue":"8","key":"10.1016\/j.phrs.2020.105010_bib0100","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.phrs.2020.105010_bib0105","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.4049\/jimmunol.167.8.4686","article-title":"AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice","volume":"167","author":"Matthys","year":"2001","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2020.105010_bib0110","doi-asserted-by":"crossref","first-page":"R188","DOI":"10.1186\/ar3158","article-title":"CXC chemokine receptor 4 expressed in T cells plays an important role in the development of collagen-induced arthritis","volume":"12","author":"Chung","year":"2010","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semcancer.2003.10.003","article-title":"The significance of cancer cell expression of the chemokine receptor CXCR4","volume":"14","author":"Balkwill","year":"2004","journal-title":"Semin. Cancer Biol."},{"issue":"15","key":"10.1016\/j.phrs.2020.105010_bib0120","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1039\/c2cs35085h","article-title":"Imaging agents for the chemokine receptor 4 (CXCR4)","volume":"41","author":"Kuil","year":"2012","journal-title":"Chem. Soc. Rev."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0125","doi-asserted-by":"crossref","DOI":"10.3390\/cells8020185","article-title":"Involvement of CXCR4 in normal and abnormal development","volume":"8","author":"Kawaguchi","year":"2019","journal-title":"Cells."},{"issue":"12","key":"10.1016\/j.phrs.2020.105010_bib0130","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.1073\/pnas.89.12.5286","article-title":"Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event","volume":"89","author":"De Clercq","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.phrs.2020.105010_bib0135","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0014-5793(02)03143-5","article-title":"Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4","volume":"527","author":"Hatse","year":"2002","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJM199807023390107","article-title":"Acute human immunodeficiency virus type 1 infection","volume":"339","author":"Kahn","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.phrs.2020.105010_bib0145","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.bcp.2008.12.014","article-title":"The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil)","volume":"77","author":"De Clercq","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2020.105010_bib0150","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1128\/AAC.44.6.1667-1673.2000","article-title":"Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers","volume":"44","author":"Hendrix","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"15","key":"10.1016\/j.phrs.2020.105010_bib0155","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1097\/QAD.0b013e32833e50bb","article-title":"CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression","volume":"24","author":"Raymond","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.phrs.2020.105010_bib0160","first-page":"5447","article-title":"Maraviroc: a review of its use in HIV infection and beyond","volume":"9","author":"Woollard","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.phrs.2020.105010_bib0165","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ejmech.2017.08.027","article-title":"An update on small molecules targeting CXCR4 as starting points for the development of anti-cancer therapeutics","volume":"139","author":"Grande","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105010_bib0170","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3389\/fimmu.2015.00276","article-title":"AMD3100\/CXCR4 inhibitor","volume":"6","author":"De Clercq","year":"2015","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0175","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/med.21464","article-title":"Harnessing CXCR4 antagonists in stem cell mobilization, HIV infection, ischemic diseases, and oncology","volume":"38","author":"Tsou","year":"2018","journal-title":"Med. Res. Rev."},{"issue":"8","key":"10.1016\/j.phrs.2020.105010_bib0180","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2003-02-0663","article-title":"Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist","volume":"102","author":"Liles","year":"2003","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0185","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1537-2995.2005.04222.x","article-title":"Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist","volume":"45","author":"Liles","year":"2005","journal-title":"Transfusion."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3816\/SCT.2004.n.008","article-title":"Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist","volume":"1","author":"H\u00fcbel","year":"2004","journal-title":"Support. Cancer Ther."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0195","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bjhh.2015.02.006","article-title":"Mobilization and collection of CD34(+) cells for autologous transplantation of peripheral blood hematopoietic progenitor cells in children: analysis of two different granulocyte-colony stimulating factor doses","volume":"37","author":"Eid","year":"2015","journal-title":"Rev. Bras. Hematol. Hemoter."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1543-2912(13)60060-0","article-title":"The role of plerixafor (AMD3100) in mobilizing hematopoietic progenitor cells in patients with hematologic malignancies","volume":"3","author":"Reddy","year":"2006","journal-title":"Support. Cancer Ther."},{"key":"10.1016\/j.phrs.2020.105010_bib0205","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000315736","article-title":"FDA review summary: mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation","volume":"78","author":"Brave","year":"2010","journal-title":"Oncology."},{"issue":"6","key":"10.1016\/j.phrs.2020.105010_bib0210","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1128\/JVI.72.6.5035-5045.1998","article-title":"In vivo distribution of the human immunodeficiency virus\/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5","volume":"72","author":"Zhang","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.phrs.2020.105010_bib0215","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0166-3542(95)00936-1","article-title":"Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1","volume":"29","author":"Est\u00e9","year":"1996","journal-title":"Antiviral Res."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0220","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/jvi.70.2.689-696.1996","article-title":"The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication","volume":"70","author":"de Vreese","year":"1996","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0225","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nm0198-072","article-title":"AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor","volume":"4","author":"Donzella","year":"1998","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.phrs.2020.105010_bib0230","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1128\/AAC.41.12.2616","article-title":"Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120","volume":"41","author":"De Vreese","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0235","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1128\/AAC.40.3.750","article-title":"Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry","volume":"40","author":"Datema","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0240","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0002-9440(10)62562-X","article-title":"AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity","volume":"160","author":"Lukacs","year":"2002","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0245","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/01.qai.0000137371.80695.ef","article-title":"Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection","volume":"37","author":"Hendrix","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.phrs.2020.105010_bib0250","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM196404022701402","article-title":"\u201cMYELOKATHEXIS\u201d--a NEW FORM OF CHRONIC GRANULOCYTOPENIA. REPORT OF a CASE","volume":"270","author":"Zuelzer","year":"1964","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2020.105010_bib0255","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0002-9343(90)90187-I","article-title":"A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia","volume":"89","author":"Wetzler","year":"1990","journal-title":"Am. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2020.105010_bib0260","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2004-06-2289","article-title":"WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12","volume":"105","author":"Balabanian","year":"2005","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0265","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ng1149","article-title":"Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease","volume":"34","author":"Hernandez","year":"2003","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0270","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/MOH.0b013e32831ac557","article-title":"WHIM syndrome: congenital immune deficiency disease","volume":"16","author":"Kawai","year":"2009","journal-title":"Curr. Opin. Hematol."},{"issue":"10","key":"10.1016\/j.phrs.2020.105010_bib0275","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood.V81.10.2496.2496","article-title":"A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia","volume":"81","author":"Dale","year":"1993","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0280","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1398-9995.2005.00756.x","article-title":"Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency","volume":"60","author":"Favre","year":"2005","journal-title":"Allergy."},{"issue":"18","key":"10.1016\/j.phrs.2020.105010_bib0285","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2011-07-368084","article-title":"The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome","volume":"118","author":"McDermott","year":"2011","journal-title":"Blood."},{"issue":"18","key":"10.1016\/j.phrs.2020.105010_bib0290","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1182\/blood-2011-06-360586","article-title":"The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome","volume":"118","author":"Dale","year":"2011","journal-title":"Blood."},{"issue":"15","key":"10.1016\/j.phrs.2020.105010_bib0295","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2013-09-527226","article-title":"A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor","volume":"123","author":"McDermott","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.phrs.2020.105010_bib0300","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/132679","article-title":"Multifocal and multicentric glioblastoma with leptomeningeal gliomatosis: a case report and review of the literature","volume":"2013","author":"Shakur","year":"2013","journal-title":"Case Rep. Med."},{"issue":"6685","key":"10.1016\/j.phrs.2020.105010_bib0305","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/31269","article-title":"Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development","volume":"393","author":"Zou","year":"1998","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0310","first-page":"102","article-title":"Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma","volume":"6","author":"Rempel","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0315","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ijc.23929","article-title":"Defining a role for Sonic hedgehog pathway activation in desmoplastic medulloblastoma by identifying GLI1 target genes","volume":"124","author":"Yoon","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"23","key":"10.1016\/j.phrs.2020.105010_bib0320","doi-asserted-by":"crossref","first-page":"13513","DOI":"10.1073\/pnas.2235846100","article-title":"A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors","volume":"100","author":"Rubin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"21","key":"10.1016\/j.phrs.2020.105010_bib0325","doi-asserted-by":"crossref","first-page":"E2182","DOI":"10.1073\/pnas.1404943111","article-title":"Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1\/CXCR4 in breast cancer stem cells","volume":"111","author":"Yi","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0330","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1541-7786.MCR-10-0235","article-title":"Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1\/2 in prostate cancer cells","volume":"9","author":"Chetram","year":"2011","journal-title":"Mol. Cancer Res."},{"issue":"51","key":"10.1016\/j.phrs.2020.105010_bib0335","doi-asserted-by":"crossref","first-page":"49481","DOI":"10.1074\/jbc.M206222200","article-title":"CXCR4 is a major chemokine receptor on glioma cells and mediates their survival","volume":"277","author":"Zhou","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0340","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1172\/JCI40283","article-title":"Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice","volume":"120","author":"Kioi","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"50","key":"10.1016\/j.phrs.2020.105010_bib0345","doi-asserted-by":"crossref","first-page":"83701","DOI":"10.18632\/oncotarget.13295","article-title":"CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: a genetic knockdown study","volume":"7","author":"Yadav","year":"2016","journal-title":"Oncotarget."},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0350","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.ijrobp.2017.12.257","article-title":"Inhibitors of HIF-1\u03b1 and CXCR4 mitigate the development of radiation necrosis in mouse brain","volume":"100","author":"Yang","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.phrs.2020.105010_bib0355","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cyto.2017.07.020","article-title":"Stromal cell-derived factor 1\u03b1 facilitates aneurysm remodeling in elastase-induced rabbit saccular aneurysm","volume":"102","author":"Li","year":"2018","journal-title":"Cytokine."},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0360","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jama.2019.5856","article-title":"Treat-to-Target strategies in rheumatoid arthritis-reply","volume":"322","author":"M\u00f8ller-Bisgaard","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.phrs.2020.105010_bib0365","doi-asserted-by":"crossref","first-page":"j3248","DOI":"10.1136\/bmj.j3248","article-title":"Diagnosis and early management of inflammatory arthritis","volume":"358","author":"Ledingham","year":"2017","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0370","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/art.10102","article-title":"Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice","volume":"46","author":"Blades","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.phrs.2020.105010_bib0375","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1002\/art.11219","article-title":"Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue","volume":"48","author":"Bradfield","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.phrs.2020.105010_bib0380","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1002\/art.27650","article-title":"Pathogenic role of CXCR7 in rheumatoid arthritis","volume":"62","author":"Watanabe","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"9561","key":"10.1016\/j.phrs.2020.105010_bib0385","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(07)60279-7","article-title":"Systemic lupus erythematosus","volume":"369","author":"D\u2019Cruz","year":"2007","journal-title":"Lancet (London, England)."},{"issue":"10","key":"10.1016\/j.phrs.2020.105010_bib0390","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1517\/14728220903196761","article-title":"Targeting the CXCR4\/CXCL12 axis in systemic lupus erythematosus","volume":"13","author":"Chong","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"issue":"11","key":"10.1016\/j.phrs.2020.105010_bib0395","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.27685","article-title":"Dysregulated expression of CXCR4\/CXCL12 in subsets of patients with systemic lupus erythematosus","volume":"62","author":"Wang","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0400","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J. Pathol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0405","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11864-000-0059-0","article-title":"Early cervical cancer","volume":"1","author":"Lu","year":"2000","journal-title":"Curr. Treat. Options Oncol."},{"issue":"35","key":"10.1016\/j.phrs.2020.105010_bib0410","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","article-title":"Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials","volume":"26","author":"Group M-A","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0415","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.radonc.2016.03.011","article-title":"Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study","volume":"120","author":"Sturdza","year":"2016","journal-title":"Radiother. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0420","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1200\/JCO.2002.20.3.680","article-title":"Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer","volume":"20","author":"Fyles","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2020.105010_bib0425","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1158\/0008-5472.CAN-03-3196","article-title":"Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma","volume":"64","author":"Cairns","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2020.105010_bib0430","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/1471-2407-10-225","article-title":"Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4","volume":"10","author":"Cronin","year":"2010","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.phrs.2020.105010_bib0435","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1084\/jem.20030267","article-title":"Regulation of the chemokine receptor CXCR4 by hypoxia","volume":"198","author":"Schioppa","year":"2003","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0440","first-page":"2549","article-title":"Identification of differentially expressed genes in cervical cancer by bioinformatics analysis","volume":"16","author":"Ge","year":"2018","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.phrs.2020.105010_bib0445","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ijc.31297","article-title":"Targeting the CXCL12\/CXCR4 pathway and myeloid cells to improve radiation treatment of locally advanced cervical cancer","volume":"143","author":"Lecavalier-Barsoum","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0450","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ijc.23083","article-title":"Involvement of SDF-1alpha\/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma","volume":"122","author":"Kajiyama","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.phrs.2020.105010_bib0455","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.bbagen.2009.08.001","article-title":"Glycosaminoglycans and syndecan-4 are involved in SDF-1\/CXCL12-mediated invasion of human epitheloid carcinoma HeLa cells","volume":"1790","author":"Brule","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0460","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.radonc.2013.06.019","article-title":"Hypoxia and metastasis in an orthotopic cervix cancer xenograft model","volume":"108","author":"Chaudary","year":"2013","journal-title":"Radiother. Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2020.105010_bib0465","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-16-1730","article-title":"Plerixafor improves primary tumor response and reduces metastases in cervical Cancer Treated with radio-chemotherapy","volume":"23","author":"Chaudary","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0470","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/0008-5472.CAN-06-3037","article-title":"The terminology issue for myeloid-derived suppressor cells","volume":"67","author":"Gabrilovich","year":"2007","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.phrs.2020.105010_bib0475","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju147","article-title":"Uterine cervical cancer displaying tumor-related leukocytosis: a distinct clinical entity with radioresistant feature","volume":"106","author":"Mabuchi","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.phrs.2020.105010_bib0480","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/IGC.0000000000000219","article-title":"Preoperative neutrophil-lymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery","volume":"24","author":"Zhang","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0485","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ccr.2008.01.034","article-title":"HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion","volume":"13","author":"Du","year":"2008","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.phrs.2020.105010_bib0490","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nrc2444","article-title":"The role of myeloid cells in the promotion of tumour angiogenesis","volume":"8","author":"Murdoch","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2020.105010_bib0495","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ijc.31297","article-title":"Targeting the CXCL12\/CXCR4 pathway and myeloid cells to improve radiation treatment of locally advanced cervical cancer","volume":"143","author":"Lecavalier-Barsoum","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"14","key":"10.1016\/j.phrs.2020.105010_bib0500","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1158\/0008-5472.CAN-09-4446","article-title":"Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation","volume":"70","author":"Kozin","year":"2010","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0505","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41416-019-0497-3","article-title":"Targeting CXCL12\/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy","volume":"121","author":"Lecavalier-Barsoum","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2020.105010_bib0510","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cyto.2017.04.003","article-title":"The effect of G-CSF and AMD3100 on mice treated with streptozotocin: expansion of alpha-cells and partial islet protection","volume":"96","author":"Gomez","year":"2017","journal-title":"Cytokine."},{"key":"10.1016\/j.phrs.2020.105010_bib0515","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1475-2840-10-92","article-title":"Effects of granulocyte-colony stimulating factor (G-CSF) on diabetic cardiomyopathy in Otsuka Long-Evans Tokushima fatty rats","volume":"10","author":"Lim","year":"2011","journal-title":"Cardiovasc. Diabetol."},{"issue":"7","key":"10.1016\/j.phrs.2020.105010_bib0520","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3109\/10520295.2014.899625","article-title":"Nephro-protective effect of granulocyte colony-stimulating factor in streptozotocin induced diabetic rats","volume":"89","author":"Erbas","year":"2014","journal-title":"Biotech. Histochem."},{"issue":"12","key":"10.1016\/j.phrs.2020.105010_bib0525","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0530","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.semradonc.2005.04.002","article-title":"Surgical management of pancreatic cancer","volume":"15","author":"Ujiki","year":"2005","journal-title":"Semin. Radiat. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0535","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1053\/j.gastro.2005.06.056","article-title":"CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer","volume":"129","author":"Saur","year":"2005","journal-title":"Gastroenterology."},{"issue":"11","key":"10.1016\/j.phrs.2020.105010_bib0540","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","article-title":"CXCL12 (SDF-1)\/CXCR4 pathway in cancer","volume":"16","author":"Teicher","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.phrs.2020.105010_bib0545","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/sj.bjc.6605968","article-title":"CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy","volume":"103","author":"Singh","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"50","key":"10.1016\/j.phrs.2020.105010_bib0550","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"11","key":"10.1016\/j.phrs.2020.105010_bib0555","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/JTO.0000000000000661","article-title":"A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma: a review of 12 years\u2019 experience","volume":"10","author":"Opitz","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2020.105010_bib0560","first-page":"2153","article-title":"SDF1\/CXCL12 is involved in recruitment of stem-like progenitor cells to orthotopic murine malignant mesothelioma spheroids","volume":"30","author":"Lau","year":"2010","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0565","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/path.2829","article-title":"The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma","volume":"223","author":"Li","year":"2011","journal-title":"J. Pathol."},{"issue":"7092","key":"10.1016\/j.phrs.2020.105010_bib0570","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0575","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/jim-2018-000839","article-title":"Experimental study of the inhibition effect of CXCL12\/CXCR4 in malignant pleural mesothelioma","volume":"67","author":"Li","year":"2019","journal-title":"J. Investig. Med."},{"issue":"16","key":"10.1016\/j.phrs.2020.105010_bib0580","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1158\/0008-5472.CAN-10-3143","article-title":"CXCL12\/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer","volume":"71","author":"Righi","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2020.105010_bib0585","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-8722-7-15","article-title":"A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma","volume":"7","author":"Yuan","year":"2014","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0590","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12307-012-0100-4","article-title":"The role of regulatory t cells in mesothelioma","volume":"5","author":"Ireland","year":"2012","journal-title":"Cancer Microenviron."},{"issue":"5","key":"10.1016\/j.phrs.2020.105010_bib0595","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/2326-6066.CIR-17-0530","article-title":"AMD3100 augments the efficacy of mesothelin-targeted, Immune-activating VIC-008 in mesothelioma by modulating intratumoral immunosuppression","volume":"6","author":"Li","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"10.1016\/j.phrs.2020.105010_bib0600","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0605","first-page":"271","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA"},{"issue":"13","key":"10.1016\/j.phrs.2020.105010_bib0610","first-page":"4961","article-title":"Epithelial cancer cell migration: a role for chemokine receptors?","volume":"61","author":"Scotton","year":"2001","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0615","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2006.02.036","article-title":"Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression","volume":"103","author":"Jiang","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0620","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1002\/jcp.27163","article-title":"Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro","volume":"234","author":"Liu","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0625","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1535-7163.MCT-17-0643","article-title":"A role for CXCR4 in peritoneal and hematogenous ovarian Cancer dissemination","volume":"17","author":"Figueras","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"35","key":"10.1016\/j.phrs.2020.105010_bib0630","doi-asserted-by":"crossref","first-page":"59123","DOI":"10.18632\/oncotarget.19289","article-title":"Mifepristone inhibits ovarian cancer metastasis by intervening in SDF-1\/CXCR4 chemokine axis","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget."},{"issue":"8","key":"10.1016\/j.phrs.2020.105010_bib0635","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1002\/mc.22645","article-title":"Abortifacient metapristone (RU486 derivative) interrupts CXCL12\/CXCR4 axis for ovarian metastatic chemoprevention","volume":"56","author":"Zheng","year":"2017","journal-title":"Mol. Carcinog."},{"issue":"6","key":"10.1016\/j.phrs.2020.105010_bib0640","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.hoc.2018.07.011","article-title":"Emerging role and future directions of immunotherapy in advanced ovarian Cancer","volume":"32","author":"Chodon","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"5","key":"10.1016\/j.phrs.2020.105010_bib0645","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1096\/fj.201802067RR","article-title":"Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment","volume":"33","author":"Zeng","year":"2019","journal-title":"FASEB J."},{"issue":"8","key":"10.1016\/j.phrs.2020.105010_bib0650","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrgastro.2010.100","article-title":"Hepatocellular carcinoma: a global view","volume":"7","author":"Yang","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0655","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/cmi.2014.102","article-title":"CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not","volume":"12","author":"Neve Polimeno","year":"2015","journal-title":"Cell. Mol. Immunol."},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0660","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1535-6108(04)00079-0","article-title":"Metadherin, a cell surface protein in breast tumors that mediates lung metastasis","volume":"5","author":"Brown","year":"2004","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.phrs.2020.105010_bib0665","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/carcin\/bgp064","article-title":"Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis","volume":"30","author":"Yu","year":"2009","journal-title":"Carcinogenesis."},{"issue":"6","key":"10.1016\/j.phrs.2020.105010_bib0670","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100372","article-title":"AEG-1 promotes anoikis resistance and orientation chemotaxis in hepatocellular carcinoma cells","volume":"9","author":"Zhou","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0675","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell."},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0680","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/carcin\/bgr226","article-title":"MicroRNA-622 functions as a tumor suppressor by targeting K-Ras and enhancing the anticarcinogenic effect of resveratrol","volume":"33","author":"Han","year":"2012","journal-title":"Carcinogenesis."},{"key":"10.1016\/j.phrs.2020.105010_bib0685","doi-asserted-by":"crossref","first-page":"8494","DOI":"10.1038\/ncomms9494","article-title":"EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma","volume":"6","author":"Liu","year":"2015","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0690","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.26790","article-title":"Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha\/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice","volume":"59","author":"Chen","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.phrs.2020.105010_bib0695","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.27665","article-title":"CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice","volume":"61","author":"Chen","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2020.105010_bib0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105406","article-title":"Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway","volume":"192","author":"Jang","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"6","key":"10.1016\/j.phrs.2020.105010_bib0705","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrc1098","article-title":"The pathogenesis of cancer metastasis: the\u2019 seed and soil\u2019 hypothesis revisited","volume":"3","author":"Fidler","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"23","key":"10.1016\/j.phrs.2020.105010_bib0710","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1158\/0008-5472.CAN-04-1844","article-title":"CXCR4 regulates growth of both primary and metastatic breast cancer","volume":"64","author":"Smith","year":"2004","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0715","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.canlet.2009.02.005","article-title":"CXCR4 receptor positive spheroid forming cells are responsible for tumor invasion in vitro","volume":"280","author":"Krohn","year":"2009","journal-title":"Cancer Lett."},{"issue":"12","key":"10.1016\/j.phrs.2020.105010_bib0720","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1111\/cas.13823","article-title":"Forkhead box C1 boosts triple-negative breast cancer metastasis through activating the transcription of chemokine receptor-4","volume":"109","author":"Pan","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.phrs.2020.105010_bib0725","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.canlet.2018.01.009","article-title":"CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation","volume":"418","author":"Zhou","year":"2018","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.phrs.2020.105010_bib0730","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1158\/1078-0432.CCR-05-1940","article-title":"Human melanoma metastases express functional CXCR4","volume":"12","author":"Scala","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0735","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1078-0432.CCR-15-3140","article-title":"ADAM17 is a tumor promoter and therapeutic target in western diet-associated Colon Cancer","volume":"23","author":"Mustafi","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.phrs.2020.105010_bib0740","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1158\/0008-5472.CAN-09-3828","article-title":"Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells","volume":"70","author":"Dessein","year":"2010","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.phrs.2020.105010_bib0745","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1161\/01.CIR.0000147780.30124.CF","article-title":"Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury","volume":"110","author":"Abbott","year":"2004","journal-title":"Circulation."},{"issue":"10","key":"10.1016\/j.phrs.2020.105010_bib0750","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1111\/j.1582-4934.2012.01539.x","article-title":"Myocardial regeneration by transplantation of modified endothelial progenitor cells expressing SDF-1 in a rat model","volume":"16","author":"Schuh","year":"2012","journal-title":"J. Cell. Mol. Med."},{"issue":"5","key":"10.1016\/j.phrs.2020.105010_bib0755","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/cns.12238","article-title":"Endogenous endothelial progenitor cells participate in neovascularization via CXCR4\/SDF-1 axis and improve outcome after stroke","volume":"20","author":"Mao","year":"2014","journal-title":"CNS Neurosci. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0760","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/jpet.108.141085","article-title":"Blockade of CXCL12\/CXCR4 axis ameliorates murine experimental colitis","volume":"327","author":"Mikami","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.phrs.2020.105010_bib0765","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","article-title":"Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation","volume":"14","author":"Pusic","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"7","key":"10.1016\/j.phrs.2020.105010_bib0770","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3109\/14653249.2012.681042","article-title":"Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization","volume":"14","author":"Sancho","year":"2012","journal-title":"Cytotherapy."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0775","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/10428194.2013.802783","article-title":"Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor","volume":"55","author":"Farina","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0780","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/trf.12265","article-title":"Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma","volume":"54","author":"Lanza","year":"2014","journal-title":"Transfusion."},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0785","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.transci.2015.05.011","article-title":"Optimizing mobilization strategies in difficult-to-mobilize patients: the role of plerixafor","volume":"53","author":"Goker","year":"2015","journal-title":"Transfus. Apher. Sci."},{"issue":"5","key":"10.1016\/j.phrs.2020.105010_bib0790","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.clpt.2004.12.268","article-title":"A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100","volume":"77","author":"Lack","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0795","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3816\/CLM.2007.n.009","article-title":"AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma","volume":"7","author":"Holtan","year":"2007","journal-title":"Clin. Lymphoma Myeloma"},{"issue":"9","key":"10.1016\/j.phrs.2020.105010_bib0800","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1111\/trf.13141","article-title":"A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the \"on-demand\" scheme of administration at French autologous hematopoietic stem cell transplant programs","volume":"55","author":"Chabannon","year":"2015","journal-title":"Transfusion."},{"issue":"6","key":"10.1016\/j.phrs.2020.105010_bib0805","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/bmt.2014.33","article-title":"A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program","volume":"49","author":"Sheppard","year":"2014","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.phrs.2020.105010_bib0810","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/trf.12979","article-title":"Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor","volume":"55","author":"Bilgin","year":"2015","journal-title":"Transfusion."},{"issue":"7","key":"10.1016\/j.phrs.2020.105010_bib0815","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.bbmt.2014.03.023","article-title":"Effectiveness of an algorithm-based approach to the utilization of plerixafor in patients undergoing chemotherapy-based stem cell mobilization","volume":"20","author":"Chow","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"8","key":"10.1016\/j.phrs.2020.105010_bib0820","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1111\/trf.13076","article-title":"A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration","volume":"55","author":"Storch","year":"2015","journal-title":"Transfusion."},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0825","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jca.21563","article-title":"UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy","volume":"33","author":"Douglas","year":"2018","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.phrs.2020.105010_bib0830","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cell.2017.11.003","article-title":"Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell","volume":"172","author":"Hoggatt","year":"2018","journal-title":"Cell."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0835","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1172\/JCI200418847","article-title":"Bone marrow-derived progenitor cells in pulmonary fibrosis","volume":"113","author":"Hashimoto","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0840","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1165\/rcmb.2006-0187OC","article-title":"Role of the SDF-1\/CXCR4 axis in the pathogenesis of lung injury and fibrosis","volume":"37","author":"Xu","year":"2007","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0845","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1667\/RR2886.1","article-title":"Plerixafor, a CXCR4 antagonist, mitigates skin radiation-induced injury in mice","volume":"178","author":"Kim","year":"2012","journal-title":"Radiat. Res."},{"issue":"11","key":"10.1016\/j.phrs.2020.105010_bib0850","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079768","article-title":"Inhibition of the CXCL12\/CXCR4-axis as preventive therapy for radiation-induced pulmonary fibrosis","volume":"8","author":"Shu","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0855","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/HP.0000000000000458","article-title":"Progenitor cell mobilization by gamma-tocotrienol: a promising radiation countermeasure","volume":"111","author":"Singh","year":"2016","journal-title":"Health Phys."},{"key":"10.1016\/j.phrs.2020.105010_bib0860","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/rpd\/ncu223","article-title":"Tocols induce G-CSF and mobilise progenitors that mitigate radiation injury","volume":"162","author":"Singh","year":"2014","journal-title":"Radiat. Prot. Dosimetry"},{"issue":"1","key":"10.1016\/j.phrs.2020.105010_bib0865","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jrr\/rrt088","article-title":"Alpha-tocopherol succinate- and AMD3100-mobilized progenitors mitigate radiation combined injury in mice","volume":"55","author":"Singh","year":"2014","journal-title":"J. Radiat. Res."},{"issue":"5","key":"10.1016\/j.phrs.2020.105010_bib0870","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3109\/09553002.2013.762137","article-title":"Alpha-tocopherol succinate-mobilized progenitors improve intestinal integrity after whole body irradiation","volume":"89","author":"Singh","year":"2013","journal-title":"Int. J. Radiat. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0875","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1053\/j.seminoncol.2012.02.002","article-title":"Strategies to use immune modulators in therapeutic vaccines against cancer","volume":"39","author":"Berzofsky","year":"2012","journal-title":"Semin. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0880","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1172\/JCI200422674","article-title":"Progress on new vaccine strategies against chronic viral infections","volume":"114","author":"Berzofsky","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.phrs.2020.105010_bib0885","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1172\/JCI21926","article-title":"Progress on new vaccine strategies for the immunotherapy and prevention of cancer","volume":"113","author":"Berzofsky","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2020.105010_bib0890","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","article-title":"Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses","volume":"22","author":"Sakaguchi","year":"2004","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0895","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.coi.2004.01.010","article-title":"Immunoregulatory T cells in tumor immunity","volume":"16","author":"Terabe","year":"2004","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2020.105010_bib0900","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00262-005-0048-z","article-title":"Role of immature myeloid cells in mechanisms of immune evasion in cancer","volume":"55","author":"Kusmartsev","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.phrs.2020.105010_bib0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188361","article-title":"Targeting tumor microenvironment in ovarian cancer: premise and promise","author":"Jiang","year":"2020","journal-title":"Biochimica et Biophysica Acta Reviews on Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2020.105010_bib0910","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","article-title":"Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges","volume":"17","author":"Martin","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0915","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/ni.3082","article-title":"PTENtiating autoimmunity through Treg cell deregulation","volume":"16","author":"Ray","year":"2015","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0920","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/ni.3076","article-title":"Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses","volume":"16","author":"Shrestha","year":"2015","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105010_bib0925","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/ni.3077","article-title":"Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability","volume":"16","author":"Huynh","year":"2015","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2020.105010_bib0930","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.immuni.2013.01.013","article-title":"An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos","volume":"38","author":"Sharma","year":"2013","journal-title":"Immunity."},{"issue":"10","key":"10.1016\/j.phrs.2020.105010_bib0935","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500845","article-title":"The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment","volume":"1","author":"Sharma","year":"2015","journal-title":"Sci. Adv."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820313189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820313189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:19:41Z","timestamp":1760912381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820313189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":187,"alternative-id":["S1043661820313189"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105010","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105010"}}